Therapeutic Asset Ratings

474 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
db107-rrv High Grade Glioma	University of California, San Francisco	P2	B (58)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Fallopian Tube Clear Cell Adenocarcinoma	Mayo Clinic	P2	B (58)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Fallopian Tube Endometrioid Adenocarcinoma	Mayo Clinic	P2	B (58)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Ovarian Endometrioid Adenocarcinoma	Mayo Clinic	P2	B (58)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Primary Peritoneal Serous Adenocarcinoma	Mayo Clinic	P2	B (58)
Recombinant Human Adenovirus Type 5 Malignant Melanoma	Fujian Cancer Hospital	P2	B (58)
Olvimulogene Nanivacirepvec Platinum-resistant Ovarian Cancer	Genelux Corporation	P3	B (57)
flt201 Gaucher Disease, Type 1	Spur Therapeutics	P1/2	B (57)
gc101 Efficacy	Shanghai Juncell Therapeutics	P1/2	B (57)
gc101 Safety	Shanghai Juncell Therapeutics	P1/2	B (57)
Grt-C901 Colorectal Neoplasms	Gritstone bio, Inc.	P2/3	B (57)
Adv-Tk Non Small Cell Lung Cancer	Candel Therapeutics, Inc.	P3	B (56)
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101) Hepatocellular Carcinoma	Fudan University	P3	B (56)
oh2 Melanoma	Binhui Biopharmaceutical Co., Ltd.	P3	B (56)
aav2-gdnf Parkinson's Disease	AskBio Inc	P2	CCC (55)
gc101 Melanoma	Shanghai Juncell Therapeutics	P2	CCC (55)
recombinant, non-replicating adeno-associated virus serotype 8 (rAAV8) vector, encoding a codon-optimised miniaturised version of human dystrophin (microdystrophin variant ABD1-H1-R1-R2-R3-H3-R24-H4-CR-CT194), under control of a synthetic muscle-specific promoter (SPc5-12) and a small synthetic polyadenylation signal; flanked by AAV2 inverted terminal repeats. The expressed microdystrophin variant contains the actin-binding domain 1 (ABD1), four rod domains (R1-3, R24), three hinge domains (H1, H3, H4) and a cysteine rich (CR) domain; it also features the proximal portion of the C-terminal domain, amino acids 3361-3554 (CT194) Duchenne Muscular Dystrophy	REGENXBIO Inc.	P2/3	CCC (55)
vrt106 HCC	Guangzhou Virotech Pharmaceutical Co., Ltd.	P2/3	CCC (55)
Adv-Tk Prostate Cancer	Candel Therapeutics, Inc.	P3	CCC (54)
GIROCTOCOGENE FITELPARVOVEC TRANSGENE INSERT Hemophilia A	Pfizer	P3	CCC (54)
Imnn-001 Ovarian Cancer	Imunon	P3	CCC (54)
Olvimulogene Nanivacirepvec Primary Peritoneal Cancer	Genelux Corporation	P3	CCC (54)
Etbx-071 High-risk Prostate Cancer	ImmunityBio, Inc.	P2	CCC (54)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells AIDS-Related Burkitt Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (54)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells AIDS-Related Plasmablastic Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (54)

Showing 51 to 75 of 474 assets

PreviousPage 3 of 19Next